Ibdenc

25/05/2026

On the occasion of World IBD Day, AIG Hospitals and IBDENC proudly launch the IBDENC Journal - a new platform dedicated to advancing research, education, and collaboration in Inflammatory Bowel Disease.

Together, we continue our commitment towards innovation, awareness, and better patient care in IBD.

Ibdenc

20/05/2026

01/05/2026

✅ Editorial Recommendations – May 2026

This month, Ibdenc highlights 7 key publications from leading journals, reflecting important advancements in inflammatory bowel disease (IBD) research and management.

📄 Bowel Ultrasound
1. Predictive value of bowel ultrasound for treatment response in IBD
2. Bowel ultrasound in pediatric Crohn’s disease
3. Ultrasound parameters to measure bowel damage in Crohn’s disease
📄 Update on Ustekinumab
4. Ustekinumab vs Tofacitinib in anti-TNF experienced UC – real-world data
5. Ustekinumab in pediatric Crohn’s disease
6. Ustekinumab in ileal stricturing Crohn’s disease
📄 Diet & Gut Health
7. Effect of dietary emulsifiers on the intestines – a Randomized Controlled Trial
👉 Explore more at: www.ibdenc.org

22/04/2026

Severe ulcerative colitis doesn’t always mean surgery. New research shows how personalized infliximab therapy can help doctors predict risk and improve outcomes.

Watch now: https://youtu.be/nnKXzGH2a18
Ibdenc

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with ASUC

09/04/2026

✅ Editorial Recommendations – April 2026
This month, Ibdenc highlights five important publications from leading journals, showcasing key advancements in inflammatory bowel disease (IBD) research and management.

📄 Statin therapy reduces stricture risk in Crohn’s disease
📄 Personalized infliximab dosing improves outcomes in acute severe ulcerative colitis
📄 Ustekinumab vs infliximab in perianal Crohn’s disease: comparative effectiveness
📄 Rising burden of inflammatory bowel disease in India (1990–2019 analysis)
📄 Updated colorectal surveillance guidelines in IBD

👉 Explore more at: www.ibdenc.org

30/03/2026

🔰Artificial Intelligence is reshaping how we assess disease activity in IBD clinical trials.

This video breaks down the latest IOIBD consensus on using AI for endoscopic and histologic evaluation—highlighting its potential to improve accuracy, efficiency, and consistency while supporting clinical decision-making.

▶️ Watch now: https://youtu.be/47FKA9of4YA

Source: Journal of Crohn’s and Colitis (Oxford Academic)

Artificial Intelligence is transforming how we assess disease activity in inflammatory bowel disease (IBD) clinical trials.In this video, we break down the I...

27/03/2026

🚀 Advancing IBD Care Through Innovation & Expertise

Organized by the Department of IBD, AIG Hospitals, the IUS Preceptorship in IBD brings together leading experts and clinicians for an immersive learning experience in Intestinal Ultrasound (IUS).

A platform focused on enhancing clinical skills, knowledge exchange, and improving patient care in IBD.

📸 Glimpses from the workshop

17/03/2026

Cyclic exclusive enteral nutrition (EEN) may offer a powerful non-pharmacologic strategy to sustain remission in paediatric Crohn’s disease.

The CD-HOPE trial shows significantly lower relapse rates with cyclic EEN compared to partial enteral nutrition (49% vs 76%) over 12 months-supporting its role in maintaining drug-free remission.

A promising step toward nutrition-led disease management in selected patients.

This video summarizes key findings from the CD-HOPE randomized trial evaluating nutritional maintenance strategies in paediatric Crohn’s disease. The study c...

12/03/2026

✅Editorial Recommendations – March 2026
This month, IBD-ENC highlights five important publications from leading journals, showcasing key advancements in inflammatory bowel disease (IBD) research and management.

📄A systematic review evaluates the effectiveness and safety of JAK inhibitors in acute severe ulcerative colitis

📄The SHINE-1 trial investigates the efficacy and safety of mirikizumab in paediatric ulcerative colitis

📄A 10-year follow-up of the LIR!C trial compares ileocaecal resection versus infliximab for ileal Crohn’s disease

📄An IOIBD consensus paper explores the role of artificial intelligence in assessing endoscopic and histologic endpoints in IBD trials

📄A meta-analysis reviews the potential role of the Mediterranean diet in the treatment of IBD

Together, these studies highlight progress in therapeutics, clinical trial methodology, and supportive lifestyle strategies in IBD care.

👉 Explore more at: www.ibdenc.org

25/02/2026

Longer Steroid Taper Improves Remission in Moderate–Severe Ulcerative Colitis.
A randomized trial shows that extending oral steroid tapering to 10 weeks significantly increases steroid-free remission at six months compared with a 6-week taper, with similar safety outcomes.



Know more:

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial.Thi...